Human rotavirus (HRV) serotypes were studied from diarrheal stool specimens in children in 7 regions of Japan (Sapporo, Tokyo, Maizuru, Osaka, Kagawa, Kurume, and Saga) from 1984 to 1997 by enzyme immunoassay (EIA) with serotype-specific monoclonal antibodies against serotypes 1, 2, 3 and 4. In addition, reverse transcription-polymerase chain reaction (RT-PCR) was conducted for analysis of "others" which included nonserotypable and mixed-serotype rotavirus specimens by EIA.
predominance in rotavirus diarrhea3,4). The rotavirus genome is comprised of 11 segments of doublestranded RNA, each of which codes for a distinct viral protein. Two outer capsid proteins, VP 4 and VP 7, are involved in virus neutralization and the genes encoding these proteins segregate independently. The neutralization specificity carried on VP 4 is designated as P serotype (for protease-sensitive protein) and VP 7 is designated as G serotype (for glycoprotein) 5). So far at least 14 G serotypes have been recognized among animal rotaviruses. Ten different G types (serotypes 1-6, 8-10, and 12) have been distinguished from human rotaviruses6). Although the epidemiological importance of the four major serotypes (1-4) has been indicated by their worldwide distribution, the importance of strains with the newly described serotypes 5, 6, 8, 9, 10 and 12 remains unknown7).
The present study investigated the incidence of HRV serotypes over time in 7 regions in Japan (Tokyo, Sapporo, Maizuru, Osaka, Kagawa, Saga and Kurume) from July, 1984 to June, 1997 by using enzyme immunoassay (EIA) with serotype-specific monoclonal antibodies. In addition, reverse transcriptionpolymerase chain reaction (RT-PCR) was conducted to analyse rotavirus-positive and nonserotypable/ mixed-serotype specimens by EIA from 1995-1997.
Materials and Methods
Fecal specimens Table 1 Oligonucleotide primers for PCR amplification to HRV diluted 1 to 10,000 in 2.5% skim milk in PBST was added after the plates were washed three times. The plates were shaken for 1 hr at room temperature. After the plates were washed three times, 100 ul of peroxidase conjugated goat IgG antibody to rabbit IgG diluted 1 in 3,000 in 2.5% skim milk in PBST was added and the plates were shaken for 1 hr at room temperature. The plates were washed four times with PBST, and then 100 ul of OPD-H2O2 was added. Absorbance was measured at 450 nm with a micro-EIA reader. If reactivity was more than 2-fold greater than the other serotypes and more than 0.2 OD in each EIA test it was regarded as a positive reaction. 
Serotyping (genotyping) by RT-PCR

Results
Distribution of serotypes Table 2 shows the number of rotavirus-positive stool specimens in 7 regions of Japan from 1984 to 1997 by EIA. Among a total of 3756 rotavirus-positive specimens, 3439 (91.6%) could be assigned to serotypes 1, 2, 3 and 4. The other 317 specimens were not determined because of no reactivity to serotypespecific monoclonal antibodies or reactivity with two or more serotype-specific monoclonal antibodies. 
R T-PCR of rotavirus-positive and nonserotypable specimens
RT-PCR was conducted on 12 specimens which were rotavirus-positive and nonserotypable by EIA (Table 3) . These specimens were collected in Tokyo, Maizuru, Sapporo and Kurume from 1995 to 1997. Serotype 1 was determined in 6 specimens. Another 5 specimens were positive by either first round PCR with Beg 9 and End 9 primers, or, second round PCR with VP 7-1' primer, but the serotype was not determined. The last specimen was still negative by RT-PCR.
RT-PCR of specimens with mixed-serotypes
As shown in Table 3 While this retrospective survey of rotavirus serotypes over more than 10 years and of more than 3000 rotavirus-positive specimens is one of the largest studies published to our knowledge, it still had limitations. Each region was not selected as part of a representative sampling of each region or population in Japan. Areas were selected without balancing the rates of detection. In addition, most regions could not be observed sequentially during the 13 years. The age and clinical symptoms of the patients were not recorded in each region, so we could not include them in the results. These limitations in this data, however, do not invalidate this sequential analysis of serotype distribution based on large numbers of patients.
Serotype 1 was the most predominant in all 7 regions (70.5%) with serotypes 2, 3 and 4 occurring at relatively low frequencies (9.6%, 6.2% and 5.2%, respectively).
Our results correlated with a report in 1989, in which serotype 1 was detected most often (54%) , followed by serotype 2 (18%), serotype 3 (12%) , and serotype 4 (11%) in Europe, North and South America, Africa, and Asia11). In this study the predominant serotypes rarely varied between regions or with time. For example, Possible reasons why twelve specimens were nonserotypable by EIA include : (1) EIA is less sensitive than RT-PCR [symbol A, B in Table 3 ], (2) the common antigen of the VP 6 inner capsid was present but the serotype-specific antigen of the VP 7 outer capsid was lost[symbol A to E in Table 3 ], (3) virus antigen had changed so that monoclonal antibodies did not recognise it, but virus RNA was still detectable by RT-PCR [symbol A, B, C. D in Table 3 ], (4) there are rotavirus serotypes other than 1, 2, 3 and 4 [symbol A, D, E in Table 3 ], or (5) group common antibody for screening cross-reacted with antigens other than rotavirus (non specific reaction) [symbol E in Table 3 ].
Explanations for why the other 45 specimens were mixed-serotypable by EIA include: (1) Antigens of 2 or more serotypes were present in a specimen [symbol I, S in Table 3 ], (2) there was diversity of antigens within a serotype as reported previously14,15) and the virus reacted with 2 or more serotype-specific monoclonal antibodies [symbol F to A in 3]. Another question is why the "other" appeared mostly in Kurume in 1995-1996. We are planning to sequence the specimens to determine possible intragenic recombination16) and viruses which belong to serotypes 5, 6, 10 and 12.
Primary infection of rotavirus was detected in 96% of children under two years of age17) . The infection causes about 870,000 deaths each year in developing countries. In the United States, rotavirus is associated with 3% of all hospitalized children who are under 5 years of age, which translates to a staggering 55,000 to 70,000 hospitalizations per year, with medical and indirect costs of $1 billion18,19). Therefore, several oral live-rotavirus vaccines have been evaluated in large field trials. These data will provide the key to understanding the epidemiological characteristics of rotavirus before vaccines are introduced. More epidemiological studies are essential for the development of a vaccine.
